Ganaxolone

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, November 8, 2019
GABAA receptor positive allosteric modulators, Neurosteroids, Health sciences, Pregnanes, Anticonvulsants, Ketones, Health, Neurology, Ganaxolone, Pharmaceutical industry, Allosteric modulator, Marinus

The stock options were granted as an inducement material to the new employee entering into employment with Marinus in accordance with NASDAQ Listing Rule 5635(c)(4), and are subject to the terms and conditions of a stock option agreement covering the grant.

Key Points: 
  • The stock options were granted as an inducement material to the new employee entering into employment with Marinus in accordance with NASDAQ Listing Rule 5635(c)(4), and are subject to the terms and conditions of a stock option agreement covering the grant.
  • Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of ganaxolone, which offers a new mechanism of action, demonstrated efficacy and safety, and convenient dosing to improve the lives of patients suffering from epilepsy and depression.
  • Ganaxolone is a positive allosteric modulator of GABAAthat acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant and anti-anxiety effects.
  • Marinus undertakes no obligation to update or revise any forward-looking statements.

Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter Financial Results

Retrieved on: 
Wednesday, November 6, 2019
Psychoactive drugs, GABAA receptor positive allosteric modulators, Sedatives, Anticonvulsants, Ganaxolone, Ketones, Pregnanes, Benzodiazepine

Marinus remains committed to becoming a fully-integrated, CNS-focused player in both orphan epilepsies and hospital-based critical care indications, said Scott Braunstein, M.D., Chief Executive Officer of Marinus.

Key Points: 
  • Marinus remains committed to becoming a fully-integrated, CNS-focused player in both orphan epilepsies and hospital-based critical care indications, said Scott Braunstein, M.D., Chief Executive Officer of Marinus.
  • 14 of the 17 patients failed first-line benzodiazepine treatment, and then failed two or more second-line anti-epileptic drugs prior to receiving ganaxolone.
  • Positive trends in health outcomes such as length of hospital stay were reported for patients in the target dose cohort.
  • Marinus undertakes no obligation to update or revise any forward-looking statements.

Marinus Pharmaceuticals Appoints Joe Hulihan, M.D., as Chief Medical Officer

Retrieved on: 
Tuesday, October 29, 2019
Anticonvulsants, Ganaxolone, Ketones, Pregnanes, Sedatives, Marinus, CDKL5, Humans, Names, Medical research

RADNOR, Pa., Oct. 29, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (Marinus or Company), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy, depression and other neuropsychiatric disorders, today announced that Joe Hulihan, MD, has been appointed Chief Medical Officer.

Key Points: 
  • RADNOR, Pa., Oct. 29, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (Marinus or Company), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy, depression and other neuropsychiatric disorders, today announced that Joe Hulihan, MD, has been appointed Chief Medical Officer.
  • On behalf of the entire Marinus team and Board of Directors, I welcome Joe at this exciting time at Marinus and thank Lorianne for her dedicated service, said Scott Braunstein, MD, Chief Executive Officer of Marinus.
  • I am very proud of our accomplishments since I joined as CMO in 2017, especially the initiation of two phase 3 clinical trials in children with debilitating CDKL5 deficiency disorder and PCDH19-related epilepsy, said Dr. Lorianne Masuoka, outgoing Chief Medical Officer at Marinus.
  • I am confident the Company will successfully carry forward the development of ganaxolone to improve the lives of patients suffering from life-threatening medical conditions.

Marinus Phase 2 Clinical Data on Ganaxolone in RSE Presented at Neurocritical Care Society Meeting

Retrieved on: 
Thursday, October 17, 2019
Health sciences, Pharmacology, Health, Ketones, Pharmacokinetics, Ganaxolone, Pregnanes, Sedatives, Dose-ranging study

A target dose of ganaxolone has been identified for advancement to Phase 3 and this is supported by pharmacokinetic (PK) data, presented for the first time at the meeting today.

Key Points: 
  • A target dose of ganaxolone has been identified for advancement to Phase 3 and this is supported by pharmacokinetic (PK) data, presented for the first time at the meeting today.
  • We are grateful these data were selected for a platform presentation and recognized by the Neurocritical Care Society, said Dr. Scott Braunstein, Chief Executive Officer of Marinus.
  • These data provide compelling evidence that IV ganaxolone has the potential to change the treatment paradigm for RSE with rapid onset of impressive activity paired with a manageable safety profile.
  • The Phase 2 RSE proof-of-concept clinical trial is an open-label, efficacy, safety and PK, dose-finding study conducted at 5 sites in the U.S.

Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Retrieved on: 
Friday, August 23, 2019
GABAA receptor positive allosteric modulators, Neurosteroids, Pregnanes, Ketones, Anticonvulsants, Ganaxolone, Chemistry, Medical research, Pharmacology

The stock options were granted as inducements material to the new employees entering into employment with Marinus in accordance with NASDAQ Listing Rule 5635(c)(4), and are subject to the terms and conditions of a stock option agreement covering the grant.

Key Points: 
  • The stock options were granted as inducements material to the new employees entering into employment with Marinus in accordance with NASDAQ Listing Rule 5635(c)(4), and are subject to the terms and conditions of a stock option agreement covering the grant.
  • Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of ganaxolone, which offers a new mechanism of action, demonstrated efficacy and safety, and convenient dosing to improve the lives of patients suffering from epilepsy and depression.
  • Ganaxolone is a positive allosteric modulator of GABAA that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant and anti-anxiety effects.
  • Marinus undertakes no obligation to update or revise any forward-looking statements.

Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter Financial Results

Retrieved on: 
Thursday, August 8, 2019
GABAA receptor positive allosteric modulators, Anticonvulsants, Ganaxolone, Ketones, Pregnanes, Sedatives, Epilepsy, Medicine, Health, Medical specialties

RADNOR, Pa., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business update on its clinical development activities and reported its financial results for the second quarter ended June 30, 2019.

Key Points: 
  • RADNOR, Pa., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business update on its clinical development activities and reported its financial results for the second quarter ended June 30, 2019.
  • Dr. Braunstein continued, We look forward to our Phase 2 RSE results later this quarter and continue to be encouraged by the potential of our orphan epilepsy franchise with ganaxolone.
  • IV ganaxolone is administered as adjunctive second-line treatment after patients have failed at least one second-line IV anti-epileptic drug.
  • Marinus undertakes no obligation to update or revise any forward-looking statements.